BACKGROUND Mostly of liver cancer in the world is caused by hepatitis B and C virus. Liver cancer occurs within 10-29 years after the virus is infected. If have liver cirrhosis, you can develop cancer after 5-10 years. According to the study in Mongolia 2014, C virus infection is 9.5% and B virus infection is 10.6%, high prevalence of hepatitis B, C and liver cirrhosis. Designed by Sysmex Corporation of Japan, possible analyze from blood, non invasive, sensitive and specific, M2BPGi liver cirrhosis marker. It is necessary to investigate the relationship between hepatitis B and C viruses and M2BPGi liver cirrhosis marker. METHODS M2BPGi liver cirrhosis marker measured total patients number 283. Of this patients 172 cases infected hepatitis B and C viruses, 78 patients with hepatitis B virus infection and 94 patients hepatitis C virus infection. All tests performed by full automatic analyzers Sysmex HISCL-5000, JEOL BM-6010, in the Laboratory department, Medipas Hospital, Orkhon province. RESULT Of the 283 patients who received the M2BPGi screening, 33% had C virus, 28% B virus, 4% had B and C virus co-infected, and 35% had no virus. Of the 172 patients infected with hepatitis B and C virus, man 97 (56%), woman 75 (44%). The majority of patients (72%) have liver function abnormality. Of patients with B and C viruses 115 (67%) were positive for M2BPGi liver cirrhosis marker. M2BPGi positive patients with 68 (59%) had C virus, 47 (41%) had B viruses. CONCLUSION Men are more likely to be infected with hepatic viruses. 67% of patients with hepatitis B and C viruses have M2BPGi liver cirrhosis marker positive. The likelihood of a change M2BPGi liver cirrhosis marker, more likely associated hepatitis C virus infection, than B virus infection. The presence of liver cirrhosis in adults under 45 years of age B virus is relatively high compared to C virus infection.

Introduction: Over 800,000 people in the world contract HCC each year and approximately 700,000 die from the disease. HCC is the 6th most common cancer in the world. HCC is the 3rd leading cause of cancer deaths in the world. 2/3 of liver cancer deaths are caused by hepatitis. In the U.S, HCV infection is the more common cause of HCC, while in Asia and Africa, HBV is more common. Mongolia ranks first in the world in mortality from liver cancer, indicating the need for early detection and treatment of cirrhosis. Sysmex Corporation has introduced for HISCL series analyser, a new cirrhosis marker M2BPGi of non-invasive, blood-testing. In 2016, the test was introduced at Medipas Hospital in Orkhon province. It is possible to study the advantages and significance of the marker for use in clinical practice. Materials and methods: From a total of 385 patients who underwent M2BPGi marker testing in 2016-2017Medipas hospital laboratory, data from a total of 283 patients tested for hepatitis B and C virus and M2BRGi markers were selected. A comparison of age, sex, and test parameters of a total of HCVab and HBsAg positive 172 patients tested for Total bilirubin, GPT, GOT, GGT, AFP and M2BPGi. HCV Ab, HBsAg, AFP, M2BPGi markers were analyzed by SysmexHISCL-5000 fully automated immunological analyzer, Liver function tests were performed with a fully automatic biochemical analyzer JEOL Biomajesty BM6010/C. Results: Of the M2BPGi marker tested 283 patients 94 (33%) were infected with the C virus, 78 (28%) were with the B virus,11 (4%) were co-infected with B and C viruses, 100 (35%) no any viral infection. Of the 172 patients diagnosed with hepatitis B and C virus infection, 97 (56%) were male, 75 (44%) were female. In terms of age, 72% of the population is over 45 years old.
Of the 172 patients, 115 (67%) had M2BPGi marker abnormal or > 1.0 COI. Of the M2BPGi marker abnormal patients, 47 (41%) were infected with the B virus and 68 (59%) with the C virus. In terms of age, 27.7% of hepatitis B patients and 10.3% of hepatitis C patients were under 45 years of age, 72.3% of hepatitis B patients and 89.7% of hepatitis C virus patients were over 45 years of age.
Hepatitis B and C viruses are slightly more common in men than in women. The majority of patients infected with the hepatitis virus over the age of 45. The majority of patients with hepatitis virus have abnormal liver function. Increased M2BPGi markers in people under the age of 45 with hepatitis B virus infection are relatively higher for hepatitis B virus infection than for C virus infection. Conclusions The M2BPGi marker was abnormal in 67% of hepatitis virus infected patients. It has been observed that the probability of an increase in M2BPGi marker is slightly higher in hepatitis C virus infection than in hepatitis B virus infection.